Advances in Recellularization of Decellularized Liver Grafts with Different Liver (Stem) Cells: Towards Clinical Applications
Overview
Biophysics
Cell Biology
Molecular Biology
Affiliations
Liver transplantation is currently the only curative therapy for patients with acute or chronic liver failure. However, a dramatic gap between the number of available liver grafts and the number of patients on the transplantation waiting list emphasizes the need for valid liver substitutes. Whole-organ engineering is an emerging field of tissue engineering and regenerative medicine. It aims to generate transplantable and functional organs to support patients on transplantation waiting lists until a graft becomes available. It comprises two base technologies developed in the last decade; (1) organ decellularization to generate a three-dimensional (3D) extracellular matrix scaffold of an organ, and (2) scaffold recellularization to repopulate both the parenchymal and vascular compartments of a decellularized organ. In this review article, recent advancements in both technologies, in relation to liver whole-organ engineering, are presented. We address the potential sources of hepatocytes and non-parenchymal liver cells for repopulation studies, and the role of stem-cell-derived liver progeny is discussed. In addition, different cell seeding strategies, possible graft modifications, and methods used to evaluate the functionality of recellularized liver grafts are outlined. Based on the knowledge gathered from recent transplantation studies, future directions are summarized.
Decellularized extracellular matrix-based disease models for drug screening.
Chen Z, Wang J, Kankala R, Jiang M, Long L, Li W Mater Today Bio. 2024; 29:101280.
PMID: 39399243 PMC: 11470555. DOI: 10.1016/j.mtbio.2024.101280.
The Prospect of Hepatic Decellularized Extracellular Matrix as a Bioink for Liver 3D Bioprinting.
Shi W, Zhang Z, Wang X Biomolecules. 2024; 14(8).
PMID: 39199406 PMC: 11352484. DOI: 10.3390/biom14081019.
Hussein K, Ahmadzada B, Correa J, Sultan A, Wilken S, Amiot B Bioact Mater. 2024; 40:280-305.
PMID: 38973992 PMC: 11226731. DOI: 10.1016/j.bioactmat.2024.06.001.
Nair D, Weiskirchen R Curr Issues Mol Biol. 2024; 46(1):262-278.
PMID: 38248320 PMC: 10814863. DOI: 10.3390/cimb46010018.
Organoid-guided precision hepatology for metabolic liver disease.
Osonoi S, Takebe T J Hepatol. 2024; 80(5):805-821.
PMID: 38237864 PMC: 11828489. DOI: 10.1016/j.jhep.2024.01.002.